Yamaguchi K, Abe K, Kameya T, Adachi I, Taguchi S, Otsubo K, Yanaihara N
Cancer Res. 1983 Aug;43(8):3932-9.
Gastrin-releasing peptide (GRP) is known to be a bombesin-like peptide present in mammalian tissues. Using GRP radioimmunoassay specific for carboxyl-terminal portion, the immunoreactive GRP (IR-GRP) content of 5 fetal lungs, 38 adult lungs, and 131 primary lung tumors was determined. All fetal lung extracts contained IR-GRP ranging from 31 to 140 ng/g, wet weight. IR-GRP was present in 7 to 21% of normal adult lungs and lung carcinomas other than small-cell carcinoma; the amount was not very large except in two cases of adenocarcinoma, in which 110 and 140 ng/g of IR-GRP were detected. In the case of small-cell carcinoma, IR-GRP was found in 23 of the 31 cases examined (74%), and nine (29%) of these contained large amounts of IR-GRP (100 to 14,000 ng/g). As for carcinoid tumors, IR-GRP was found in five of the 12 cases examined (42%), and large amounts of IR-GRP were detected in two cases (5,100 to 130,000 ng/g). Immunohistochemically, IR-GRP was found in the neuroendocrine cells of fetal lungs and in the tumor cells of primary lung tumors. When these tissue extracts were examined by bombesin radioimmunoassay that recognizes bombesin but not GRP, they did not contain immunoreactive bombesin, suggesting that IR-GRP in these tissues is more similar to GRP than to bombesin. Sephadex G-50 gel filtration always revealed two peaks of IR-GRP in both fetal lungs and IR-GRP-producing tumors. One was eluted at the position corresponding to that of porcine GRP (Peak 1) and the other, at the position just behind that of porcine GRP (14-27) (Peak 2). In the five fetal lungs, Peak 2 comprised more than 83% of the total IR-GRP. In the 12 IR-GRP-producing tumors examined, the ratio of these two peaks differed from case to case. Our data indicate that IR-GRP, which is present in fetal lung, is often produced by primary lung tumors, especially by small-cell carcinoma and carcinoid tumor, with molecular size heterogeneity.
胃泌素释放肽（GRP）是一种存在于哺乳动物组织中的蛙皮素样肽。使用针对羧基末端部分的GRP放射免疫分析法，测定了5个胎儿肺、38个成人肺和131个原发性肺肿瘤中免疫反应性GRP（IR-GRP）的含量。所有胎儿肺提取物中IR-GRP的含量为31至140 ng/g（湿重）。IR-GRP存在于7%至21%的正常成人肺和非小细胞癌的肺癌中；除两例腺癌外，含量都不是很高，这两例腺癌中检测到的IR-GRP含量分别为110和140 ng/g。在小细胞癌的病例中，31例中有23例（74%）检测到IR-GRP，其中9例（29%）含有大量IR-GRP（100至14,000 ng/g）。至于类癌肿瘤，12例中有5例（42%）检测到IR-GRP，2例检测到大量IR-GRP（5,100至130,000 ng/g）。免疫组织化学分析显示，IR-GRP存在于胎儿肺的神经内分泌细胞和原发性肺肿瘤的肿瘤细胞中。当用识别蛙皮素但不识别GRP的蛙皮素放射免疫分析法检测这些组织提取物时，未发现免疫反应性蛙皮素，这表明这些组织中的IR-GRP与GRP的相似性高于与蛙皮素的相似性。Sephadex G-50凝胶过滤法在胎儿肺和产生IR-GRP的肿瘤中均始终显示出两个IR-GRP峰。一个在与猪GRP相对应的位置洗脱（峰1），另一个在猪GRP（14 - 27）之后的位置洗脱（峰2）。在5个胎儿肺中，峰2占总IR-GRP的83%以上。在检测的12个产生IR-GRP的肿瘤中，这两个峰的比例因病例而异。我们的数据表明，存在于胎儿肺中的IR-GRP通常由原发性肺肿瘤产生，尤其是小细胞癌和类癌肿瘤，且具有分子大小异质性。
